Advanced Enzyme Technologies Ltd (IN:ADVENZYMES)
:ADVENZYMES
Top Page
Advanced Enzyme Technologies Ltd
(ADVENZYMES)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹300.00
▼(-1.07% Downside)
Action:ReiteratedDate:10/07/25
Advanced Enzyme Technologies Ltd scores well in financial performance due to its strong revenue and profit growth, solid margins, and effective leverage management. However, technical analysis indicates bearish momentum and valuation metrics suggest the stock is fairly priced but not a standout in terms of value. The absence of earnings call data and corporate events limits further insights.
Positive Factors
Consistent revenue and profit growth
Sustained top-line and earnings growth across reporting periods indicates durable demand for enzyme and probiotic products in multiple end-markets. Recurring consumable use by B2B customers supports predictable revenues and underpins medium-term expansion and reinvestment capacity.
Negative Factors
Slight decline in EBIT margin
A falling EBIT margin, even if modest, signals potential stresses in operating efficiency or margin mix that can erode operating leverage over time. If not addressed through productivity or pricing actions, it could constrain free cash available for growth and R&D investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue and profit growth
Sustained top-line and earnings growth across reporting periods indicates durable demand for enzyme and probiotic products in multiple end-markets. Recurring consumable use by B2B customers supports predictable revenues and underpins medium-term expansion and reinvestment capacity.
Read all positive factors
Advanced Enzyme Technologies Ltd (ADVENZYMES) vs. iShares MSCI India ETF (INDA)
Market Cap
₹32.77B
Dividend Yield1.7%
Average Volume (3M)13.78K
Price to Earnings (P/E)19.9
Beta (1Y)1.10
Revenue Growth14.11%
EPS Growth7.47%
CountryIN
Employees323
SectorHealthcare
Sector Strength45
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)2.80
Shares Outstanding111,926,800
10 Day Avg. Volume10,375
30 Day Avg. Volume13,779
Financial Highlights & Ratios
PEG Ratio-13.34
Price to Book (P/B)2.27
Price to Sales (P/S)5.07
P/FCF Ratio28.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.2
Revenue Forecast (FY)₹8.91B
Advanced Enzyme Technologies Ltd Business Overview & Revenue Model
Company Description
Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for human healthcare and animal nutrition, fr...
How the Company Makes Money
ADVENZYMES primarily makes money by selling enzyme- and probiotic-based products to business customers (B2B) and, where applicable, through branded or finished formulations sold via channel partners. Its revenue model is centered on (1) product sa...
Advanced Enzyme Technologies Ltd Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.07B | 6.37B | 6.23B | 5.41B | 5.29B | 5.00B |
| Gross Profit | 4.80B | 3.07B | 4.64B | 3.98B | 4.09B | 3.95B |
| EBITDA | 2.53B | 2.27B | 2.27B | 1.79B | 2.09B | 2.41B |
| Net Income | 1.47B | 1.31B | 1.33B | 1.06B | 1.20B | 1.46B |
Balance Sheet | ||||||
| Total Assets | 16.92B | 16.21B | 15.35B | 14.22B | 12.68B | 11.53B |
| Cash, Cash Equivalents and Short-Term Investments | 6.19B | 5.88B | 5.48B | 4.86B | 3.74B | 3.17B |
| Total Debt | 346.54M | 393.50M | 473.08M | 334.99M | 347.30M | 279.63M |
| Total Liabilities | 1.58B | 1.53B | 1.64B | 1.38B | 1.27B | 1.22B |
| Stockholders Equity | 14.85B | 14.21B | 13.24B | 12.35B | 10.89B | 9.71B |
Cash Flow | ||||||
| Free Cash Flow | 463.75M | 1.15B | 990.56M | 1.02B | 941.15M | 1.43B |
| Operating Cash Flow | 647.13M | 1.49B | 1.41B | 1.40B | 1.22B | 1.63B |
| Investing Cash Flow | -307.26M | -990.44M | -646.49M | -2.98B | -249.12M | -260.33M |
| Financing Cash Flow | -652.83M | -692.02M | -592.38M | -257.98M | -273.75M | -263.10M |
Advanced Enzyme Technologies Ltd Technical Analysis
Neutral
303.25
Price Trends
287.62
Positive
297.06
Negative
310.81
Negative
Market Momentum
-3.55
Negative
57.18
Neutral
89.40
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ADVENZYMES, the sentiment is Neutral. The current price of 303.25 is above the 20-day moving average (MA) of 277.61, above the 50-day MA of 287.62, and below the 200-day MA of 310.81, indicating a neutral trend. The MACD of -3.55 indicates Negative momentum. The RSI at 57.18 is Neutral, neither overbought nor oversold. The STOCH value of 89.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ADVENZYMES.
Advanced Enzyme Technologies Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹31.15B | 43.39 | ― | 0.85% | ― | ― | |
65 Neutral | ₹32.77B | 19.90 | ― | 1.70% | 14.11% | 7.47% | |
61 Neutral | ₹25.41B | -74.58 | ― | ― | 5.38% | ― | |
57 Neutral | ₹30.13B | 67.80 | ― | 0.03% | 7.78% | -34.68% | |
57 Neutral | ₹22.01B | 20.54 | ― | 0.49% | -0.29% | -29.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ADVENZYMES
Advanced Enzyme Technologies Ltd
292.75
20.52
7.54%
IN:DCAL
Dishman Carbogen Amcis Ltd.
162.10
-42.40
-20.73%
IN:GUFICBIO
Gufic Biosciences Limited
300.50
-29.61
-8.97%
IN:MOREPENLAB
Morepen Laboratories Limited
40.17
-9.81
-19.63%
IN:RPGLIFE
RPG Life Sciences Limited
1,883.25
-160.41
-7.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.